Neuros Medical

Neuros Medical is focused on developing neurostimulation therapies for unmet needs to patients worldwide. The company’s patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain and chronic migraine. Neuros’ technology delivers high-frequency stimulation to sensory nerves in the

Read Story

Securus Medical Group

Securus Medical Group is developing clinical tools to monitor core body temperature within body cavities. Its technology will provide clinicians with a simple to use, real-time, noncontact, thermal map of body cavity tissue temperature. This information will guide the physician to achieve the desired clinical outcome without risk of injury to surrounding tissue. Securus Medical Group’s

Read Story

SironRX Therapeutics

SironRX Therapeutics is developing novel therapies that promote dermal wound repair and reduce scarring. The company’s therapeutic platform is based on the delivery of Stromal cell-Derived Factor 1 (SDF-1), which has been shown to promote tissue repair by recruiting stem cells to the damaged organ. SDF-1 has also been shown to prevent cell death and promote new

Read Story

SPR Therapeutics

SPR™ Therapeutics is commercializing a novel therapy for severe pain with its patented peripheral nerve stimulation products. The company’s pipeline of neurostimulation pain therapies will exploit the same physiologic mechanism of action, proprietary technology and clinical approach. The first product to be commercialized is the SMARTPATCH™ PNS System, which is a short-term, minimally invasive system

Read Story

Synapse Biomedical, Inc

Synapse Biomedical is focused on the development and commercialization of minimally invasive neurostimulation technologies for the diagnosis and treatment of neurodegenerative impairments. Compared to traditional surgeries and devices, the company’s minimally invasive surgical interventions and respiratory assist procedures reduce risks to both patients and surgeons and are performed at substantially lower cost. Synapse Biomedical, Inc

Read Story

Thermalin Diabetes, LLC

Thermalin Diabetes is developing clinically superior, second-generation insulin analogs for the rapidly growing $12 billion insulin market. Thermalin’s patent-pending compounds include rapid-, intermediate- and long-acting analogs. With patents expiring on existing analogs in the next three to four years, Thermalin looks to form partnerships with large pharmaceutical companies that wish to market superior, next-generation insulin

Read Story

Zuga Medical

Zuga Medical is a medical device company developing a series of proprietary products, accessories and programs to make dental implants simpler and more cost-effective. The company’s FDA-approved Zuga® implant system allows general practice dentists to perform procedures that were previously the domain of oral surgeons. By simplifying and streamlining implant placement and restoration, dentists can

Read Story